{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T15:50:47Z","timestamp":1740153047737,"version":"3.37.3"},"reference-count":0,"publisher":"The Journal of Rheumatology","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The aim of this study was to evaluate the response of ear, nose, and throat (ENT) symptoms to different immunosuppressive therapies in patients with antineutrophil cytoplasmic antibody\u2013associated vasculitis (AAV).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this cohort study, patients with AAV treated between January 2010 and April 2020 at 2 Dutch hospitals were included. Clinical, histological, and laboratory data were collected retrospectively. ENT involvement was defined as follows: (1) \u2265 1 ENT symptom according to the Birmingham Vasculitis Activity Score (version 3; BVAS3), and\/or (2) presence of saddle nose deformity. Associations between therapy and ENT activity were assessed using logistic regression analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 320 patients with AAV were included, of whom 209 (65.3%) had ENT involvement at some point throughout the disease course. In these 209 patients, median age at disease onset was 52.0 years (IQR 40.0-62.0) and 45.5% were male. Median BVAS3 was 12.0 (IQR 6.0-18.0) at diagnosis. Despite immunosuppressive therapy, 50% (n = 77) of the patients had ENT symptoms at relapse and 29.1% (n = 59) had ENT activity at their last visit. No statistically significant difference in ENT activity at last visit was observed between patients treated with oral or intravenous cyclophosphamide (CYC, n = 137) compared to rituximab (RTX, n = 55; adjusted odds ratio 0.59, 95% CI 0.33-1.06;<jats:italic>P<\/jats:italic>= 0.08). Lower age at disease onset and female sex were independently associated with ENT activity at last follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this cohort, CYC and RTX therapy had similar therapeutic effects on ENT symptoms in AAV. Persistent ENT activity is a common feature despite immunosuppressive therapy.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.220343","type":"journal-article","created":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T12:20:16Z","timestamp":1665836416000},"page":"jrheum.220343","source":"Crossref","is-referenced-by-count":0,"title":["Immunosuppressive Therapies in Ear, Nose, and Throat Involvement in Antineutrophil Cytoplasmic Antibody\u2013Associated Vasculitis: Results From a Multicenter Retrospective Cohort Study"],"prefix":"10.3899","author":[{"given":"Roline M.","family":"Krol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline M.","family":"Schaap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paco M.J.","family":"Welsing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Klaasen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilde H.F.","family":"Remmelts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. Christiaan","family":"Hagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marloes W.","family":"Heijstek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2546-312X","authenticated-orcid":false,"given":"Julia","family":"Spierings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2022,10,15]]},"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.220343","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T13:38:28Z","timestamp":1675258708000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.220343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,15]]},"references-count":0,"alternative-id":["10.3899\/jrheum.220343"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.220343","relation":{},"ISSN":["0315-162X","1499-2752","0315-162X"],"issn-type":[{"type":"print","value":"0315-162X"},{"type":"electronic","value":"1499-2752"},{"type":"print","value":"0315-162X"}],"subject":[],"published":{"date-parts":[[2022,10,15]]}}}